Tamtam Try Tamtam free
ZEISS Group logo

ZEISS Group account plan

Optics and optoelectronics manufacturing

At a glance

ZEISS is a foundation-owned German optics and optoelectronics group: €11,896m revenue in FY2024/25 and about 47,400 employees.

ZEISS develops, produces and sells semiconductor lithography optics, industrial metrology, microscopes, medical technology, eyeglass lenses and other optical products, from its headquarters in Oberkochen, Germany. It is represented in around 50 countries with around 40 R&D centres and 30 production sites, and earns 94% of revenue outside Germany. In FY2024/25 (to 30 September 2025) revenue reached a record €11,896m (+9%), EBIT was €1,552m (13% margin) and consolidated profit €952m, with 46,622 employees at year-end and about 47,400 at 31 March 2026. The sole shareholder is the Carl Zeiss Foundation, whose statutes prohibit an IPO; Carl Zeiss Meditec AG is a listed subsidiary in which the group holds a 59.1% capital share.

Business units

Strategic priorities

Competitiveness programme
Announced in June 2026, it targets annual savings of "several hundred million euros over the next three years" versus FY2024/25 through cost-structure changes in the segments, corporate administration and country organisations; job reductions are expected.
ZEISS Agenda 2030
Succeeds #agenda25 and was presented internally in November 2025, aiming to serve customer needs more quickly and generate sustainable profitable growth.
Data- and process-driven organisation
The transformation started three years ago continues, including the rollout of modern CRM and AI solutions and a Digital Competence Center with more than 1,200 digital experts.
ProfitUp at Carl Zeiss Meditec
More than €200m of annual profit improvement by FY2028/29, with up to 1,000 positions affected, divestment of non-mission-critical products and an adjusted EBITA margin above 15% by FY2028/29.
Reducing dependence on SMT
The CEO names years of declining momentum in the direct-to-market segments and the resulting dependency on SMT as a fundamental challenge; the owners aim for a balanced portfolio.

Latest results

In H1 FY2025/26 (six months to 31 March 2026) group revenue was €5.841bn, up 1% from €5.794bn, and EBIT rose €33m to €955m. SMT grew 6% to €2,612m after a recent strong upturn in demand, while IQR (-3%) and MED (-7%) declined on a very difficult market and negative currency effects, and Consumer Markets grew 1%. R&D stayed at 14% of revenue and the equity ratio at 51%. ZEISS expects no improvement in the second half and is preparing for further revenue decline in the direct-to-market segments; the FY2025/26 outlook calls for a slightly lower revenue level and an EBIT margin of around 11%.

Investments and deals

EUV capacity and Jena site
Capex on property, plant and equipment was €1,294m in FY2024/25, notably for next-generation EUV production and the new high-tech site in Jena (about 3,500 employees).
Beyond Gravity Lithography acquisition
Acquired Beyond Gravity's Lithography division for €99.4m, effective 29 November 2024, adding actuator and mechatronic production and R&D capacity.
Brighten Optix acquisition
Agreed on 4 June 2025 to acquire Taiwan's largest rigid contact lens maker (about 180 employees, €24m revenue in 2024), for orthokeratology lenses.
R&D spending
€1,731m of R&D expensed in FY2024/25 (15% of revenue), with 7,364 R&D staff and about 13,000 patents.
Financing
A €900m promissory note loan placed on 29 October 2024 and a €200m syndicated loan on 29 September 2025, plus an undrawn €1,300m revolving facility.

Challenges and risks

Concentration on semiconductors
SMT made about 42% of FY2024/25 revenue and depends on ASML and chip makers' capex; without it the group would have reported stagnation.
Weak direct-to-market segments
IQR, MED and CM face lower research budgets, price pressure, new Chinese competitors and falling order volumes; FY2024/25 orders of €11,315m were below revenue.
Inefficient structures
The CEO says structures built during the growth years are no longer efficient in all areas; Vision Care in Aalen cuts 180 full-time jobs by the end of 2026 and the Aalen-Ebnat metrology campus is on hold.
Geopolitics and trade
Tariffs, protectionism and export restrictions in the technology sector and for rare raw materials, plus strong negative currency effects.
Medical technology setbacks
Carl Zeiss Meditec's H1 FY2025/26 revenue fell 5.7% to €991m, hit by weaker IOL sales in China after a licence revocation, and a goodwill write-down that may exceed €100m is possible.

What leadership says

“We are acting from a position of strength before the circumstances force us to act.”

Andreas Pecher, President and CEO · ZEISS half-year figures press release, 9 June 2026

“after years of strong growth, it is especially important now to optimize cost structures so that we continue to generate the funds for future investments.”

Stefan Müller, CFO · ZEISS half-year figures press release, 9 June 2026

“Our innovation arm is strong. However, our commercial arm remains underdeveloped in many markets.”

Andreas Pecher, interim CEO of Carl Zeiss Meditec AG · Carl Zeiss Meditec H1 2025/26 earnings call, 12 May 2026

“sustained, substantial investment in digitalization and in research and development is the foundation for further growth achieved through technological differentiation and innovation, even in a challenging environment.”

Dr. Michael Bolle, Supervisory Board chair · ZEISS Group Annual Report 2024/25, 18 December 2025

Where a supplier can help

Cost-structure and shared-services efficiency
Tied to the competitiveness programme's savings target in administration and country organisations: process automation, outsourcing and procurement-optimisation providers fit the plan.
CRM, SAP and commercial excellence
Tied to ProfitUp's reinvestment in SAP and a group-wide CRM and to the stated underdeveloped commercial arm: CRM implementation, sales-enablement and data partners are directly relevant.
Semiconductor capacity build-out
Tied to the EUV capex and the Jena site: suppliers of precision components, clean-room infrastructure and manufacturing automation can support SMT capacity.
Localisation and best-cost sourcing
Tied to Meditec's plan to move manufacturing and selected R&D to China and best-cost countries and to optimise supply chains: contract manufacturers and supply-chain advisers fit.
AI and data in the transformation
Tied to the data- and process-driven organisation priority: AI, data-platform and analytics vendors can support the group-wide transformation.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like ZEISS Group?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about ZEISS Group

What does ZEISS do?

ZEISS is an optics and optoelectronics group that makes semiconductor lithography optics for ASML, industrial metrology, microscopes, medical technology and eyeglass lenses, organised in four segments: SMT, IQR, MED and Consumer Markets.

What is ZEISS's revenue?

Revenue was a record €11,896m in FY2024/25 (to 30 September 2025), up 9%, with EBIT of €1,552m. In H1 FY2025/26 revenue was €5.841bn, up 1%.

How many employees does ZEISS have?

About 47,400 people worldwide at 31 March 2026, against 46,622 at 30 September 2025.

Who leads ZEISS?

Andreas Pecher has been President and CEO since 1 April 2025, with Stefan Müller as CFO. The group is wholly owned by the Carl Zeiss Foundation.

What is ZEISS's strategy?

The ZEISS Agenda 2030 and a group-wide competitiveness programme targeting annual savings of several hundred million euros over three years, while continuing above-average investment in innovation.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)